Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by gregoooon May 03, 2013 8:59am

84 Views

Post# 21334176

RE: RE: RE: so what's so hard to understand

they had $411,000 at the end of 2012 and are making about $10,000 per day so another $300,000x3= $900,000, so approx. $1,300,000 cash-my estimate. I am not sure but they should be getting some of the money held by the Columbian goverment as they have meet the drilling requirements of 3 blocks so they should get the deposits back-they still owe $1,875,000 to their partner for the last 2 wells. Capital markets for raising cash are the sh%ts,so what can they do-carryon the way they are? imo. hope the current wells keep producing, Omega gets the 2 new wells tested and producing ,SMQ retains their 24.75% and get enough cash to drill a couple of wells later in the year.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload